Equillium, Inc.
EQHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Equillium, Inc. (EQ) is listed under Biotechnology. At a $78.0M market cap, Equillium, Inc. ranks as a micro-cap company within healthcare. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Market Cap
$78.0M
Beta
1.92
P/E (TTM)
—
P/E (Fwd)
-5.19
EPS (TTM)
$-0.14
EPS (Fwd)
$-0.24
ROE
-59.0%
ROA
-34.0%
Cash
$57.2M
Total Debt
$584,000
Free CF
-$14.3M
52W Change
-10.2%
Annual Financials
Cash vs Debt
Where EQ stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, EQ finished 44.89% below its 150-day moving average ($2.25) and 40.10% below its 200-day moving average ($2.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EQ overbought or oversold?
At the October 20, 2026 close, EQ's RSI(14) was 28.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $57.2M in cash comfortably exceeding the $584K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$14.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -59.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $15.8M to $0.
Equillium, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing EQ.